trending Market Intelligence /marketintelligence/en/news-insights/trending/BTK6gMtP7WoZFJsQQ3a_Mg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Arena Pharmaceuticals heart failure drug APD418 gets fast-track tag from US FDA

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Arena Pharmaceuticals heart failure drug APD418 gets fast-track tag from US FDA

Arena Pharmaceuticals Inc.'s heart failure therapy APD418 received the U.S. Food and Drug Administration's fast-track designation.

The designation gives regulatory priority to treatments that show promise and offers incentives such as more frequent communication with the regulator and the opportunity to apply for accelerated approval and priority review.

San Diego-based Arena's therapy treats the sudden worsening of heart failure symptoms, referred to as decompensated heart failure. APD418 is being tested in an early-stage clinical trial.